Literature DB >> 19108804

Assessing prescriptions for statins in ambulatory diabetic patients in the United States: a national, cross-sectional study.

Larry W Segars1, Amanda R Lea.   

Abstract

BACKGROUND: Diabetes mellitus affects >20 million people in the United States each year, and >4000 new cases are diagnosed daily.
OBJECTIVE: This study assessed the prescription of statin medications in the ambulatory setting in US diabetic patients.
METHODS: We used data from the 2002 through 2004 National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey. All ambulatory medical visits associated with a diabetes diagnosis by the International Classification of Diseases, Ninth Revision, Clinical Modification were included. Prescriptions for statin medications were determined by searching each ambulatory visit for relevant drug names (trade and generic). Demographic characteristics were assessed, including survey year, sex, age group, race, ethnicity, payment type, region of the country, and physician's specialty and degree. Analyses used sample weights to calculate national estimates.
RESULTS: From 2002 to 2004, 10,046 (unweighted) ambulatory visits were made by diabetic patients, representing a weighted national estimate of approximately 153 million visits. A statin prescription was associated with 21.1% of all diabetic visits and 14.1% of those without a hyperlipidemia-related diagnosis. Diabetic men were more likely than diabetic women to be given a prescription for a statin (odds ratio [OR], 1.38; 95% CI, 1.09-1.73). Compared with diabetic patients treated in 2002, those treated in 2003 and 2004 were more likely to be prescribed statin therapy (2003 OR, 1.51; 95% CI, 1.02-2.24; 2004 OR, 1.48; 95% CI, 1.03-2.15). Compared with diabetic patients aged 45 to 64 years, those in younger age groups were less likely to be given a statin prescription (1-24 years OR, 0.10; 95% CI, 0.01-0.84; 25-44 years OR, 0.48; 95% CI, 0.31-0.74), and those aged 65 to 74 years were more likely to be given a statin (OR, 1.38; 95% CI, 1.01-1.90). No differences were noted for diabetic patients aged > or = 75 years.
CONCLUSIONS: From 2002 through 2004, <25% of the ambulatory medical visits by diabetic patients in the United States were associated with a statin prescription. Male sex and age up to 75 years had an increased association with statin prescription. Additional study is anticipated to assess changes in statin use in diabetic patients in the United States as updated treatment guidelines are released.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19108804     DOI: 10.1016/j.clinthera.2008.11.004

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  8 in total

1.  Building a diabetes screening population data repository using electronic medical records.

Authors:  Wen-Jan Tuan; Ann M Sheehy; Maureen A Smith
Journal:  J Diabetes Sci Technol       Date:  2011-05-01

2.  Statin use and the risk of Clostridium difficile in academic medical centres.

Authors:  Christine Anne Motzkus-Feagans; Amy Pakyz; Ronald Polk; Giovanni Gambassi; Kate L Lapane
Journal:  Gut       Date:  2012-03-22       Impact factor: 23.059

3.  Understanding gender differences in statin use among elderly Medicare beneficiaries: an application of decomposition technique.

Authors:  Sandipan Bhattacharjee; Patricia A Findley; Usha Sambamoorthi
Journal:  Drugs Aging       Date:  2012-12       Impact factor: 3.923

4.  Analysis of guidelines for screening diabetes mellitus in an ambulatory population.

Authors:  Ann M Sheehy; Grace E Flood; Wen-Jan Tuan; Jinn-ing Liou; Douglas B Coursin; Maureen A Smith
Journal:  Mayo Clin Proc       Date:  2010-01       Impact factor: 7.616

5.  Race-Sex Differences in Statin Use and Low-Density Lipoprotein Cholesterol Control Among People With Diabetes Mellitus in the Reasons for Geographic and Racial Differences in Stroke Study.

Authors:  Christopher M Gamboa; Lisandro D Colantonio; Todd M Brown; April P Carson; Monika M Safford
Journal:  J Am Heart Assoc       Date:  2017-05-10       Impact factor: 5.501

6.  The Role of EGFR/ERK/ELK-1 MAP Kinase Pathway in the Underlying Damage to Diabetic Rat Skin.

Authors:  Xinhong Ge; Zhiyun Shi; Nan Yu; Yaning Jiao; Li Jin; Jianzhong Zhang
Journal:  Indian J Dermatol       Date:  2013-03       Impact factor: 1.494

7.  Monitoring the use of lipid-lowering medication among persons with newly diagnosed diabetes: a nationwide register-based study.

Authors:  Tuulikki Vehko; Reijo Sund; Martti Arffman; Kristiina Manderbacka; Pirjo Ilanne-Parikka; Ilmo Keskimäki
Journal:  BMJ Open       Date:  2013-11-04       Impact factor: 2.692

8.  Utilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes - a nationwide cross-sectional study (TEMD dyslipidemia study).

Authors:  Fahri Bayram; Alper Sonmez; Cem Haymana; Tevfik Sabuncu; Oguzhan Sitki Dizdar; Eren Gurkan; Ayse Kargili Carlioglu; Kemal Agbaht; Didem Ozdemir; Ibrahim Demirci; Cem Barcin; Serpil Salman; Tamer Tetiker; Mustafa Kemal Balci; Nur Kebapci; Canan Ersoy; Volkan Yumuk; Peter P Toth; Ilhan Satman
Journal:  Lipids Health Dis       Date:  2020-11-11       Impact factor: 3.876

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.